- Find a clinical trial
- Destiny-Gastric 05
Gastric
Destiny-Gastric 05
A Multicenter, Randomized, Open-Label, Phase 3 Trial of Trastuzumab Deruxtecan (Enhertu®) Plus Chemotherapy Plus or Minus Pembrolizumab versus Chemotherapy Plus Trastuzumab Plus or Minus Pembrolizumab as First-line Treatment in Subjects with Unresectable, Locally Advanced or Metastatic HER2-positive Gastric or Gastroesophageal Junction (GEJ) Cancer
Trial overview
Medical Oncology
Gastric
Gastrointestinal
III
Registration number: NCT06731478
St Leonards (North Shore Health Hub)
North Shore Health Hub, Tower A, Level 1, 7 Westbourne St, St Leonards, NSW, 2065, Australia
Clinical trials enquiries
Thank you for submitting.
Thank you for submitting.
We will be in touch within 24 hours
Form submission error
An unexpected error has occurred.
You will need to complete the form again, sorry for the inconvenience.
Disclaimer:
This website is provided for information purposes only. Nothing on this website is intended to be used as medical advice, or to diagnose, treat, cure or prevent any disease. It should not be used as a substitute for your own health professional's advice. Any medical procedure or treatment carries risks. Before proceeding with treatment, you should discuss the risks and benefits of the treatment with an appropriately qualified health practitioner. Individual treatment outcomes and experiences will vary.